USA 1-800-227-2862 (BBRAUN2)

B. Braun Committed to Protecting Healthcare Workers from Exposure to Hazardous Drugs

   

The Centers for Disease Control and Prevention (CDC) estimates that approximately 8 million U.S. healthcare workers are potentially exposed to hazardous drugs, including pharmacy and nursing personnel, physicians, operating room personnel, environmental services workers, workers in research laboratories, veterinary care workers, and shipping and receiving personnel.14

According to the CDC, published studies have shown that workplace exposures to hazardous drugs can cause both acute and chronic health effects such as skin rashes, adverse reproductive outcomes (including infertility, spontaneous abortions, and congenital malformations), and possibly leukemia and other cancers. The health risk depends on how much exposure a worker has to these drugs and how toxic they are.14



To underscore its commitment to helping protect healthcare workers from exposure to hazardous drugs, B. Braun’s protective engineering device include:

- OnGuard™, a next-generation closed system drug transfer device (CSTD) with Tevadaptor™ Components

Visit the OnGuard web page to learn more about how this products can help you.

 

Resources:

[1] Li, Jie Jack (2006). Laughing Gas, Viagra, and Lipitor: The Human Stories behind the Drugs We Use. Oxford University Press. p. 8. ISBN 0-19-530099-8.
[2] US Bureau of Labor Statistics. May 2006 National and Occupational Employment and Wage Estimates. Washington DC: United States Department of Labor, Bureau of Labor Statistics; 2007.
[3] CDC (Centers for Disease Control and Prevention) Occupational Exposure to Antineoplastic Agents,
http://www.cdc.gov/niosh/topics/antineoplastic/, accesses 2/18/2013.
[4] Niosh Guidelines: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings,2004, p1.
[5] Niosh Guidelines: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings,2004.
[6]  Lawson CC, Rocheleau CM, Whelan EA, et al. Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol 2012;206:327.e1-8.
[7]  Tilyou Sarah. Cytotoxic drug residues Still Lurking in Health Care Facilities, Pharmacy Practice News. 2010;Issue 1, Vol 37:01.
[8] Niosh Guidelines: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings,2004.
[9] Occupational Safety and Health Administration (OSHA) Technical Manual, Controlling Exposure to Hazardous Drugs, Section IV Chapter 2, 1999.
[10] American Society of Health System Pharmacists. ASHP Guidelines on HAndling Hazardous Drugs. Am J Health-Syst Pharm. 2006; 63:1172-93
[11]
http://www.lni.wa.gov/safety/topics/atoz/hazardousdrugs/
[12] http://www.invw.org/chemo-main,  accessed 2/18/2013
[13]
http://www.nejm.org/doi/full/10.1056/NEJM198511073131901
[14] http://www.cdc.gov/niosh/topics/hazdrug/

 

Tevadaptor is a registered trademark of Teva Medical Ltd.